Viva Biotech (Shanghai) Ltd, a subsidiary of Viva Biotech Holdings, has announced plans to acquire an 80 per cent stake in the contract development manufacturing organisation (CDMO) Zhejiang Langhua Pharmaceutical for 2.56 billion yuan ($368 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
